ライフサイエンスコーパス: peripheral blood stem cell

1 AML cell viability without effect on normal peripheral blood stem cells.

2 ic stem cell transplantation currently using peripheral blood stem cells.

3 ients) followed by infusion of unmanipulated peripheral blood stem cells.

4 g leukapheresis for collection of autologous peripheral blood stem cells.

5 not enhance engraftment of CD34(+) selected peripheral blood stem cells.

6 al clinical applications for IL-17-mobilized peripheral blood stem cells.

7 donors, unrelated cord blood, and allogeneic peripheral blood stem cells.

8 l transplantation of ex vivo T-cell-depleted peripheral blood stem cells.

9 g hematopoietic growth factors or autologous peripheral blood stem cells.

10 e currently undertaken using G-CSF mobilized peripheral blood stem cells.

11 late as day 354 after the transplantation of peripheral-blood stem cells.

12 d tandem transplants, supported by mobilized peripheral-blood stem cells.

13 uximab and filgrastim to mobilize autologous peripheral-blood stem cells.

14 fusion of unmanipulated filgrastim mobilized peripheral blood stem cells (5.5-31.7 x 10(6) cells/kg)

15 RIC peripheral blood stem cell allo-HSCT is prospectively fe

16 nd fludarabine, followed by an infusion of a peripheral-blood stem-cell allograft from an HLA-identic

17 usions (GTs) were given following allogeneic peripheral blood stem cell (AlloPBSC) transplantation.

18 Thirteen patients received allogeneic peripheral blood stem cells and 1 received bone marrow a

19 ion that results in successful collection of peripheral blood stem cells and allows flow rates compar

20 een 9/10 and 10/10 matched grafts or between peripheral blood stem cells and bone marrow.

21 ransplantation immune reconstitution between peripheral blood stem cells and bone marrow.

22 anulocytes and monocytes mirrors TL of CD34+ peripheral blood stem cells and progenitor cells extreme

23 were correlated to TL in CD34+ hematopoietic peripheral blood stem cells and progenitor cells obtaine

24 This difference was identical for CD34+ peripheral blood stem cells and progenitor cells, monocy

25 peripheral blood cell populations, including peripheral blood stem cells and progenitor cells.

26 y-stimulating factor (G-CSF) mobilization of peripheral blood stem cells and retrovirus transduction

27 ect significant survival differences between peripheral-blood stem-cell and bone marrow transplantati

28 es included unrelated donor, matched-sibling peripheral blood stem cells, and unrelated cord blood.

29 Mobilized peripheral blood stem cells are increasingly used for th

30 nulocyte colony-stimulating factor-mobilized peripheral blood stem cells are widely used to reconstit

31 Some studies have also shown that peripheral-blood stem cells are associated with a decrea

32 by autologous marrow rescue with or without peripheral-blood stem-cell augmentation to determine the

33 ne the EC potential of human bone marrow and peripheral blood stem cells, blood vessels in sex-mismat

34 6%, and 78% of evaluable related bone marrow/peripheral blood stem cells (BM/PBSCs), unrelated BM/PBS

35 e colony-stimulating factor (G-CSF) mobilize peripheral blood stem cells by different mechanisms.

36 e transduced X-CGD patient-mobilized CD34(+) peripheral blood stem cells (CD34(+)PBSCs) with lentivec

37 We later showed that transduced CD34+ peripheral blood stem cells (CD34+ PBSCs) from this tria

38 te-macrophage colony-stimulating factor with peripheral blood stem cell collection, and etoposide-dex

39 nduction treatment, with adequate autologous peripheral blood stem-cell collection, and without persi

40 Peripheral-blood stem-cell collection was performed afte

41 Analysis of peripheral-blood stem-cell collections by molecular tech

42 fraction of the clonogenic cells from human peripheral blood stem cell concentrates were also transd

43 Three peripheral blood stem cell concentrates were collected f

44 leukocyte antigen (HLA)-matched related (MR) peripheral blood stem cells conferred protection against

45 -stimulating factor (G-CSF)-mobilized, CD34+ peripheral blood stem cells derived from a patient with

46 nulocyte colony-stimulating factor-mobilized peripheral blood stem cell donor grafts and successful t

47 In this pilot study, donor peripheral blood stem cell (DPBSC) infusions were perfor

48 has been used as a single agent to mobilize peripheral blood stem cells for allogeneic hematopoietic

49 ) to determine the feasibility of collecting peripheral blood stem cells for future use.

50 often in older patients receiving autologous peripheral blood stem cells for HD or NHL.

51 Peripheral blood stem cells from 2 rhesus monkeys were c

52 Unmanipulated bone marrow or peripheral blood stem cells from HLA-matched related-don

53 ty conditioning regimens using unmanipulated peripheral blood stem cells from human leukocyte antigen

54 ther bone marrow cells or cytokine-mobilized peripheral blood stem cells from leukocyte antigen-match

55 the transplantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings

56 liminate tumor cells from the bone marrow or peripheral blood stem cell graft without causing stem ce

57 nulocyte colony-stimulating factor-mobilized peripheral blood stem cell grafts (naive and memory T-ce

58 Allogeneic peripheral blood stem cell grafts contain about 10 times

59 T) utilizes HLA-matched donor bone marrow or peripheral blood stem cell grafts to reconstitute haemat

60 Autologous peripheral blood stem cell grafts were CD34+ selected; t

61 duals, whereas recipients of T cell-depleted peripheral-blood stem cell grafts had 28-fold and 14-fol

62 and -4, followed by reinfusion of autologous peripheral blood stem cells; group E).

63 d donors; recipients of plerixafor mobilized peripheral blood stem cells had a significantly higher i

64 rogram/kg) for 7 days and autologous CD34(+) peripheral blood stem cells harvested by leukapheresis.

65 to eliminate circulating myeloma cells from peripheral blood stem cell harvests use positive selecti

66 normal human bone marrow and mobilized human peripheral blood stem cell harvests.

67 Although the use of cytokine-mobilized peripheral blood stem cells has gained a significant mom

68 utcomes of 932 recipients of unrelated donor peripheral blood stem cell hematopoietic cell transplant

69 , pretransplant conditioning, and the use of peripheral blood stem cells in hematopoietic cell transp

70 oliferation and erythroid differentiation of peripheral blood stem cells in liquid culture.

71 ty barriers in swine, by using high doses of peripheral blood stem cells in the absence of WBI.

72 lyses of secondary end points indicated that peripheral-blood stem cells may reduce the risk of graft

73 e (PAD) induction therapy and then underwent peripheral blood stem-cell mobilisation and harvesting i

74 353 was profiled in murine and rhesus monkey peripheral blood stem cell mobilization and transplantat

75 ise ways of enhancing its myeloprotective or peripheral blood stem cell mobilization properties, whic

76 nd secondary transplant studies in mice, and peripheral blood stem cells mobilized by AMD3100 and gra

77 nonmyeloablative transplantation with CD34+ peripheral-blood stem cells, mobilized by granulocyte co

78 al effector T cells from CD34-enriched human peripheral blood stem cells modified with a lentiviral v

79 n = 29), morphologically normal BM (n = 22), peripheral blood stem cells (n = 10) from patients with

80 nulocyte-colony stimulating factor mobilized peripheral blood stem cells (n = 4), and a VCA transplan

81 bone marrow (n=8) or ex vivo T-cell-depleted peripheral blood stem cells (n=4) for chemorefractory he

82 nts received an allogeneic marrow (n = 3) or peripheral blood stem-cell (n = 18) transplant from HLA-

83 Patients received either peripheral-blood stem cells (n = 13) or bone marrow (n =

84 t its prohibition on sale did not encompass "peripheral blood stem cells" obtained through apheresis.

85 n the surface of megakaryocytes derived from peripheral blood stem cells of GT patients.

86 gh-dose therapeutic regimens with autologous peripheral blood stem cell or allogeneic bone marrow res

87 Support with peripheral blood stem cells or bone marrow and with gran

88 Autologous peripheral-blood stem cells or bone marrow were infused

89 nts were randomly assigned in a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantatio

90 A pilot study was conducted of autologous peripheral blood stem cell (PBSC) collection in 27, foll

91 s (AEs) associated with filgrastim mobilized peripheral blood stem cell (PBSC) collections in unrelat

92 xperienced by 2726 bone marrow (BM) and 6768 peripheral blood stem cell (PBSC) donors who underwent c

93 We studied whether peripheral blood stem cell (PBSC) graft iNKT-cell dose a

94 Unfractionated peripheral blood stem cell (PBSC) grafts contain measura

95 ective depletion of TN from human allogeneic peripheral blood stem cell (PBSC) grafts would reduce GV

96 Myelotoxicity can be ameliorated by peripheral blood stem cell (PBSC) infusion.

97 Peripheral blood stem cell (PBSC) infusions are associat

98 al to evaluate the safety and feasibility of peripheral blood stem cell (PBSC) mobilization in 8 SCT

99 A reliable estimate of peripheral blood stem cell (PBSC) mobilization response

100 valuated the effects of various schedules of peripheral blood stem cell (PBSC) reinfusion, granulocyt

101 High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used

102 labetuzumab), combined with doxorubicin and peripheral blood stem cell (PBSC) support in advanced me

103 ly depleted host-reactive donor T cells from peripheral blood stem cell (PBSC) transplant allografts

104 erism in 15 patients receiving an allogeneic peripheral blood stem cell (PBSC) transplant from an HLA

105 Peripheral blood stem cell (PBSC) transplantation is suc

106 Peripheral blood stem cell (PBSC) transplantation may pr

107 Allogeneic peripheral blood stem cell (PBSC) transplants from HLA-i

108 s given nonmyeloablative versus conventional peripheral blood stem cell (PBSC) transplants from HLA-m

109 ts into neutropenic recipients of autologous peripheral blood stem cell (PBSC) transplants.

110 Autologous peripheral blood stem cell (PBSC)-supported high-dose me

111 Currently, peripheral blood stem cells (PBSC) are infused after mye

112 or (G-CSF), which is widely used to mobilize peripheral blood stem cells (PBSC) from normal donors, h

113 Recipients of peripheral blood stem cells (PBSC) had faster recovery a

114 Peripheral blood stem cells (PBSC) have become the prefe

115 treated with autologous SCT, currently using peripheral blood stem cells (PBSC) mobilized by chemothe

116 e (GVHD) after transplantation of allogeneic peripheral blood stem cells (PBSC) mobilized by either r

117 Peripheral blood stem cells (PBSC) obtained from granulo

118 Autologous transplantation with peripheral blood stem cells (PBSC) results in faster hae

119 Human peripheral blood stem cells (PBSC) were obtained by leuk

120 fter autologous or allogeneic transplants of peripheral blood stem cells (PBSC), an adequate dose of

121 Peripheral-blood stem cell (PBSC) harvest and surgical r

122 /m2/d followed by infusion of bone marrow or peripheral-blood stem cells (PBSC) and recombinant human

123 Peripheral-blood stem cells (PBSC) may be used as an alt

124 I and 14 of 18 at level II received BM plus peripheral-blood stem cells (PBSC).

125 The experiences of 69 (38 marrow and 31 peripheral blood stem cell [PBSC]) donors participating

126 ult bone marrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients.

127 e children in the study donated either BM or peripheral blood stem cells (PBSCs) according to center

128 Mobilized peripheral blood stem cells (PBSCs) are widely used for

129 cyte and platelet development in which human peripheral blood stem cells (PBSCs) differentiate along

130 Sixty-five patients received peripheral blood stem cells (PBSCs) from HLA-identical s

131 Two patients received peripheral blood stem cells (PBSCs) from matched-related

132 Peripheral blood stem cells (PBSCs) have been widely ado

133 Although peripheral blood stem cells (PBSCs) have replaced bone m

134 ver, that the majority of the most primitive peripheral blood stem cells (PBSCs) in PNH appear to be

135 olony-stimulating factor (G-CSF) to mobilize peripheral blood stem cells (PBSCs) is increasing.

136 ansplantation with syngeneic plus allogeneic peripheral blood stem cells (PBSCs) is sufficient to int

137 Peripheral blood stem cells (PBSCs) mobilized with high-

138 ivity in the CD34+ Thy-1+ cell population of peripheral blood stem cells (PBSCs) of three asymptomati

139 intravenous infusions of autologous CD34(+) peripheral blood stem cells (PBSCs) that had been transd

140 e transplanted with HLA-identical allogeneic peripheral blood stem cells (PBSCs) that were selected f

141 l blood mononuclear cells (PBMCs), and CD34+ peripheral blood stem cells (PBSCs).

142 of 10 unrelated donor transplant from BM or peripheral blood stem cells (PBSCs).

143 The preferred source of the graft was peripheral blood stem cells (PBSCs).

144 nd for PIDs by using bone marrow (n = 93) or peripheral blood stem cells (PBSCs; n = 49).

145 high-dose chemotherapy (HDC) supported with peripheral-blood stem cells (PBSCs) is related to the do

146 ter high-dose chemotherapy, patients who had peripheral-blood stem cells (PBSCs) mobilized with filgr

147 marrow (BM), 609 recipients of HLA-identical peripheral-blood stem cells (PBSCs), and 675 recipients

148 cluding source of stem cells (bone marrow vs peripheral blood stem cells [PBSCs]), age, sex, graft-ve

149 e progenitor frequency in pre-HCT marrow and peripheral-blood stem cells predicted for primitive prog

150 atients with Fanconi anemia is collection of peripheral blood stem cells prior to the development of

151 Cytokine-mobilized peripheral blood stem cell products are increasingly use

152 miniature swine using a high-dose allogeneic peripheral blood stem cell protocol.

153 disease) by 2 years posttransplant among the peripheral blood stem cell recipients compared with the

154 herapy followed by autologous bone marrow or peripheral blood stem cell rescue is an alternative ther

155 ochemotherapy with autologous bone marrow or peripheral blood stem cell rescue is one of the most agg

156 y with thiotepa and etoposide and autologous peripheral blood stem-cell rescue before craniospinal ir

157 owing three cycles of high-dose therapy with peripheral blood stem-cell rescue, local radiotherapy, a

158 with three cycles of high-dose therapy with peripheral blood stem-cell rescue.

159 ith triple-tandem high-dose chemotherapy and peripheral-blood stem-cell rescue and local irradiation,

160 iple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue followed by radiation

161 te all three cycles of high-dose therapy and peripheral-blood stem-cell rescue, two patients complete

162 Moreover, mouse IL-17 adenovirus-mobilized peripheral blood stem cells rescued lethally irradiated

163 after carmustine (RR = 2.3) and with use of peripheral blood stem cells (RR = 2.4).

164 The prognostic importance of peripheral blood stem cell source in critically ill HSCT

165 Cryopreserved, pretransplant bone marrow, peripheral blood stem cell specimens, obtained at the ti

166 iving high-dose melphalan-based therapy with peripheral blood stem cell support and, hence, should no

167 advantage for growth factor mobilization and peripheral blood stem cell support compared with bone ma

168 dose chemotherapy with either bone marrow or peripheral blood stem cell support.

169 n clinical trials of tandem transplants with peripheral blood stem cells support, 470 (95%) completed

170 platelet donors, 4) increasing the yield of peripheral blood stem cells through synergy with other h

171 Sufficient peripheral blood stem cells to support two HDT cycles (C

172 Among intubated patients, those receiving peripheral blood stem cell transplant (PBSCT) had signif

173 white patients who had received a marrow or peripheral blood stem cell transplant from an HLA-identi

174 t may improve the utility and convenience of peripheral blood stem cell transplant.

175 loped a lethal case of pneumonia following a peripheral blood stem cell transplant.

176 nulocyte-colony stimulating-factor-mobilized peripheral-blood stem-cell transplant from his HLA-ident

177 We performed a nonmyeloablative allogeneic peripheral-blood stem-cell transplant in this patient to

178 Allogeneic peripheral blood stem cell transplantation (allo-PBSCT)

179 ving chemotherapy with or without autologous peripheral blood stem cell transplantation (APBSCT).

180 elphalan chemotherapy followed by autologous peripheral blood stem cell transplantation (HDM/SCT) can

181 h-dose melphalan chemotherapy and autologous peripheral blood stem cell transplantation (HDM/SCT) hav

182 t our institution with high-dose therapy and peripheral blood stem cell transplantation (PBSCT) follo

183 High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has b

184 on the improved response rates observed with peripheral blood stem cell transplantation (PBSCT) in pa

185 Allogeneic peripheral blood stem cell transplantation (PBSCT) is in

186 Peripheral blood stem cell transplantation (PBSCT) is th

187 evious multicenter phase III trial comparing peripheral blood stem cell transplantation (PBSCT) to bo

188 st survival is better in patients undergoing peripheral blood stem cell transplantation (PBSCT), but

189 tive analysis of patients with AL undergoing peripheral blood stem cell transplantation (PBSCT).

190 tients undergoing high-dose chemotherapy and peripheral blood stem cell transplantation (PSCT).

191 hy caused by JC papovavirus after autologous peripheral blood stem cell transplantation and a case ea

192 corticosteroid-requiring chronic GVHD after peripheral blood stem cell transplantation and should be

193 ed (1-2 x 10(4) T cells/kg) nonmyeloablative peripheral blood stem cell transplantation in children a

194 Peripheral blood stem cell transplantation is being used

195 NCA (131)I-MIBG with autologous peripheral blood stem cell transplantation is feasible a

196 myeloma, particularly high-dose therapy with peripheral blood stem cell transplantation, can achieve

197 arrow and lymph node irradiation (TMLI), for peripheral blood stem cell transplantation, in patients

198 Two days before allogeneic peripheral blood stem cell transplantation, miniature sw

199 n (180 mg/m(2) intravenously) and autologous peripheral blood stem cell transplantation, with marked

200 chemotherapy, whole-brain radiotherapy, and peripheral blood stem cell transplantation.

201 severity of graft-versus-host disease after peripheral blood stem cell transplantation.

202 ive patients undergoing autologous marrow or peripheral blood stem cell transplantation.

203 on, he underwent high-dose chemotherapy with peripheral blood stem cell transplantation.

204 t complications of allogeneic bone marrow or peripheral blood stem cell transplantation.

205 by autologous bone marrow transplantation or peripheral blood stem-cell transplantation (referred to

206 c graft-versus-host disease after allogeneic peripheral blood stem-cell transplantation who had sever

207 transplantation (ABMT) (n = 46) or mobilized peripheral-blood stem-cell transplantation (PBSCT) (n =

208 eated with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplantation (PBSCT) at In

209 ersus-host disease (GVHD) is increased after peripheral-blood stem-cell transplantation (PBSCT) when

210 lymphoma who underwent autologous marrow or peripheral-blood stem-cell transplantation at our instit

211 herapy followed by autologous bone marrow or peripheral-blood stem-cell transplantation for patients

212 with chronic granulomatous disease underwent peripheral-blood stem-cell transplantation from an HLA-i

213 ion in chronic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-i

214 h-dose carboplatin and etoposide followed by peripheral-blood stem-cell transplantation or autologous

215 hrough 1997 who would have been eligible for peripheral-blood stem-cell transplantation.

216 noma by means of nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

217 analyzed data from 663 unrelated marrow and peripheral blood stem cell transplants performed from 19

218 d lymphoma, or between patients who received peripheral-blood stem-cell transplants and unpurged auto

219 nd its metabolites in patients who underwent peripheral-blood stem-cell transplants.

220 f DMSO and metabolites in patients following peripheral-blood stem-cell transplants; (2) allow consid

221 that supports the concept that the mobilized peripheral blood stem cells used in clinical transplanta

222 sion (66%) in, CD34-selected, c-kit(+) human peripheral blood stem cells using a c-kit-targeted adeno

223 nter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unre

224 Peripheral blood stem cells were associated with a nonsi

225 Peripheral blood stem cells were collected from respondi

226 Unselected peripheral blood stem cells were harvested with cyclopho

227 Peripheral blood stem cells were mobilized with cyclopho

228 Peripheral blood stem cells were mobilized with cyclopho

229 sex, type of ATG used, and CD34-selection of peripheral blood stem cells were not found to be signifi

230 CI 46-66), whereas HLA-matched sibling donor peripheral blood stem cells were significantly worse (25

231 Sufficient numbers of peripheral-blood stem cells were collected in all but on

232 After induction therapy and surgery, peripheral-blood stem cells were mobilized with three cy